Review highlights chimeric antigen receptor therapy effects on acute myeloid leukemia, suggesting new treatment options.
Acute myeloid leukemia (AML) is one of the lethal hematological malignancies with high relapse rates and poor prognosis. Since chimeric antigen receptor cellular therapy has exhibited remarkable therapeutic outcomes in B‐cell malignancies, many studies have attempted to translate this success to other malignancies, including AML. Herein we review current achievements of chimeric antigen receptor‐based cell therapy in AML preclinical studies and clinical trials with potential AML‐associated cell markers. Furthermore, we discuss future prospects of chimeric antigen receptor‐based cell therapy options for patients with AML.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: